Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2024 | Mkt Perform → Outperform | William Blair | |
| 8/8/2023 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
| 7/14/2023 | Buy → Hold | Needham | |
| 1/17/2023 | Outperform → Mkt Perform | William Blair | |
| 12/9/2021 | $47.00 | Hold → Buy | Needham |
| 11/8/2021 | $70.00 → $40.00 | Hold | Stifel |
| 11/5/2021 | $72.00 → $42.00 | Market Perform | SVB Leerink |
| 11/2/2021 | $71.00 → $45.00 | Underweight → Neutral | JP Morgan |
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
William Blair upgraded Inogen from Mkt Perform to Outperform
JP Morgan downgraded Inogen from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously
Needham downgraded Inogen from Buy to Hold
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies.The study sourced data from the French national healthcare system database, the Système National des Données de Santé (SNDS). With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to dat
Stifel analyst Mathew Blackman maintains Inogen (NASDAQ:INGN) with a Hold and raises the price target from $6 to $7.
Needham analyst Mike Matson reiterates Inogen (NASDAQ:INGN) with a Hold.
10-Q - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
10-Q - Inogen Inc (0001294133) (Filer)
4 - Inogen Inc (0001294133) (Issuer)
3 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he served as General Counsel and Executive Vice President, Business Development, since 2018. Mr. Smith brings nearly thirty years of experience to the Company. Prior to joining Sirtex, Kevin served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities requirements, business development, and intellectual property. Previously, h
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024. "We continued to make significant progress on our strategic priorities in the third quarter. Our results demonstrate our team's strong commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "As we move into the fourth quarter, we remain focused on driving growth, continuing innovation, and advancing towards sustainable profitability." Third Quarter 2024 Financial Results Total revenue in the third quarter of 2024 increased 5.8% to $88.8 millio
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences: Stifel 2024 Healthcare Conference on Monday, November 18 at 9:10 a.m. Eastern Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4 at 10:30 a.m. Eastern Time A live audio webcast and archived recording of each presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/,
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024. "We continued to make significant progress on our strategic priorities in the third quarter. Our results demonstrate our team's strong commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "As we move into the fourth quarter, we remain focused on driving growth, continuing innovation, and advancing towards sustainable profitability." Third Quarter 2024 Financial Results Total revenue in the third quarter of 2024 increased 5.8% to $88.8 millio
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Inve
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2024. "I am proud of the performance of our team in the first half of 2024. We have made meaningful progress on our strategic initiatives, driving top-line growth and advancing the profile of the business toward profitability," said Kevin Smith, President and Chief Executive Officer. "We will also continue to advance our innovation pipeline and look forward to delivering best-in-class products to more respiratory patients around the world." Second Quarter 2024 Financial Results Second quarter